Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's ...
CTX-009, also known as tovecimig, is a clinical-stage bispecific antibody designed to target two critical pathways involved in tumor growth and angiogenesis: the Delta-like ligand 4 (DLL4)/Notch pathway and the vascular endothelial growth factor A (VEGF-A) pathway. By inhibiting these signaling mechanisms, it aims to reduce tumor blood supply and prevent tumor progression.
Price Range: N/A (Clinical-stage therapeutic)
Pain Points: Resistance to standard anti-angiogenic therapies and the need for more effective treatments for advanced solid tumors.
Solutions: Dual inhibition of tumor vascularization pathways, potentially enhancing therapeutic efficacy compared to single-pathway inhibitors.
Target Users: Patients with advanced malignancies and oncologists specializing in solid tumors.
Supply Chain
Contract Manufacturing Organizations (CMOs) for biologics productionClinical research organizations (CROs) for trial managementSpecialized raw material suppliers for cell culture and purification
CTX-471 is an IgG4 monoclonal antibody designed to act as an agonist (activator) of CD137, a co-stimulatory receptor on T-cells and NK cells. By activating this receptor within the tumor microenvironment, it aims to enhance the immune system's ability to recognize and destroy cancer cells.
Price Range: N/A (Clinical-stage therapeutic)
Pain Points: Tumors that have developed mechanisms to evade immune surveillance and suppression.
Solutions: Immune system stimulation via CD137 agonism, promoting anti-tumor activity of effector cells.
Target Users: Cancer patients eligible for immunotherapeutic treatment regimens.
Supply Chain
Contract Manufacturing Organizations (CMOs)Contract Research Organizations (CROs)Biologics logistics and supply network
CTX-8371 is a bispecific antibody platform candidate that targets the PD-1/PD-L1 immune checkpoint pathway at both ends. By binding simultaneously to PD-1 and PD-L1, it aims to more effectively block the inhibitory signals that tumors use to suppress the immune system, potentially offering improved efficacy over traditional checkpoint inhibitors.
Price Range: N/A (Clinical-stage therapeutic)
Pain Points: Limited efficacy or acquired resistance to current PD-1/PD-L1 blockade therapies.
Solutions: Simultaneous inhibition of both ligand and receptor in the PD-1 pathway to overcome immune evasion.
Target Users: Oncology patients who require immune checkpoint blockade treatment.
Supply Chain
Contract Manufacturing Organizations (CMOs)Contract Research Organizations (CROs)Clinical testing and laboratory service providers
